FLT3 and acute myeloid leukemia: However, more than 50% of NPM1-mut AML patients relapse; thus, for high-risk NPM1-mut patients, allogeneic stem cell transplantation (allo-HASCT) and additional treatments (such as FLT3 inhibitors) are important therapeutic choices.